New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs Tesamorelin

Retatrutide vs Tesamorelin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Growth Hormone PeptidesFat Loss & Metabolic
Tesamorelin
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
Half-Life
~10–12 days
~26 minutes
Admin Route
SubQ
SubQ
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
2 mg
Frequency
Once weekly
Once daily
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • FDA-approved for visceral fat reduction in HIV lipodystrophy
  • Significant reduction in trunk/visceral fat (average 15–20% in trials)
  • Improved triglyceride and lipid profiles
  • Potential cognitive benefits and memory improvement
  • Preserves lean mass while reducing fat
  • Natural pulsatile GH stimulation
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Injection site reactions (redness, irritation)
  • Arthralgia and joint pain
  • Peripheral edema
  • Carpal tunnel syndrome
  • +2 more
Stacks With